{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04627571",
            "orgStudyIdInfo": {
                "id": "20-000833"
            },
            "organization": {
                "fullName": "University of California, Los Angeles",
                "class": "OTHER"
            },
            "briefTitle": "Corneal Nerves After Treatment With Cenegermin",
            "officialTitle": "Structural and Functional Changes of Corneal Innervation After Treatment With Cenegermin",
            "therapeuticArea": [
                "Other"
            ],
            "study": "corneal-nerves-after-treatment-with-cenegermin"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-11",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-05-23",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2020-11-08",
            "studyFirstSubmitQcDate": "2020-11-08",
            "studyFirstPostDateStruct": {
                "date": "2020-11-13",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-11-10",
            "lastUpdatePostDateStruct": {
                "date": "2023-11-14",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Simon Fung",
                "investigatorTitle": "Principal Investigator",
                "investigatorAffiliation": "University of California, Los Angeles"
            },
            "leadSponsor": {
                "name": "University of California, Los Angeles",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Neurotrophic keratopathy (NK) is a condition in which patients have fewer or complete absence of nerves in the cornea, characterized by the reduced or absent corneal sensation. The lack of nerves in the cornea also result in damages of the cornea and in severe situation the loss of the eye.\n\nCenegermin (trade name Oxervate) is a nerve growth factor eye drops designed to treat NK, and currently, it is the only FDA-approved medication for this purpose.\n\nEven though cenegermin is effective in the majority of patients, there is a lack of understanding of how cenegermin works in the eye.\n\nIn this study, investigators aim to determine the structural and functional effects of cenegermin on the cornea, using non-invasive technologies including in vivo confocal microscopy on study participants with NK over the course of a year.",
            "detailedDescription": "Cenegermin (OxervateTM) is a recombinant human form of nerve growth factor developed by Domp\u00e9 Farmaceutici S.p.A. for patients who are diagnosed with corneal epithelial defects due to moderate to severe stages of NK."
        },
        "conditionsModule": {
            "conditions": [
                "Neurotrophic Keratitis"
            ],
            "keywords": [
                "cenegermin",
                "neurotrophic keratopathy",
                "corneal nerve",
                "corneal sensation"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "COHORT",
                "timePerspective": "PROSPECTIVE"
            },
            "enrollmentInfo": {
                "count": 40,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Patient Population",
                    "description": "Patients diagnosed with neurotrophic keratopathy.",
                    "interventionNames": [
                        "Drug: Cenegermin Ophthalmic Solution [Oxervate]"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Cenegermin Ophthalmic Solution [Oxervate]",
                    "description": "An 8-week course of topical cenegermin eye drops given 6 times daily would be started in the affected eye, in conjunction with the pre-existing medical treatment for neurotrophic keratopathy. Patients will be followed-up at 4 weeks, 6 weeks, 8 weeks, 3 months, 6 months, 9 months and 12 months (\u00b12 weeks at each time point) after treatment. At each visit, patients will be assessed to determine the corneal epithelial defect and corneal sensation.",
                    "armGroupLabels": [
                        "Patient Population"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change in corneal nerve fiber density (CNFD)",
                    "description": "To determine the changes in corneal nerve fiber density (CNFD), assessed by in vivo confocal microscopy.",
                    "timeFrame": "1 year"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Duration of changes in CNFD",
                    "description": "To determine the duration of the changes in corneal nerve fiber density (CNFD), assessed by in vivo confocal microscopy.",
                    "timeFrame": "1 year"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Presence/absence of Changes in Dry Eye Symptom",
                    "description": "To determine changes in dry eye symptom scores assessed by the Ocular Surface Disease Index in patients initiated on cenegermin for recalcitrant neurotrophic keratopathy. A score ranges from 0 to 100 with scores 0 to 12 representing normal, 13 to 22 representing mild dry eye disease, 23 to 32 representing moderate dry eye disease, and greater than 33 representing severe dry eye disease.",
                    "timeFrame": "1 year"
                },
                {
                    "measure": "Changes in Tear Production",
                    "description": "To determine the changes in tear production in patients initiated on cenegermin for recalcitrant neurotrophic keratopathy.",
                    "timeFrame": "1 year"
                },
                {
                    "measure": "Changes in Tear Characteristics",
                    "description": "To determine the changes in tear film osmolarity in patients initiated on cenegermin for recalcitrant neurotrophic keratopathy.",
                    "timeFrame": "1 year"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria\n\n1. Patients \u226518 years of age; AND\n2. Persistent corneal epitheliopathy that is refractory to treatments for \u22652 weeks; AND\n3. Evidence of decreased corneal sensitivity, defined as \u226445mm on Cochet-Bonnet esthesiometer, within the area of the persistent corneal epitheliopathy; AND\n4. Evidence of decreased corneal sensitivity, defined as above, in \u22651 corneal quadrant outside the persistent corneal epithelial defect.\n\nExclusion Criteria\n\n1. Patients with severe neurotrophic keratopathy characterized by corneal stromal ulceration involving over 75% of the total central corneal thickness and impending perforation.\n2. Patients who have used cenegermin eyedrops, autologous serum eyedrops, plasma-rich plasma eyedrops, or umbilical cord eyedrops for the treatment of neurotrophic keratopathy 8 weeks prior to study recruitment.\n3. Corneal surgery (including keratoplasty or refractive surgical procedures) within three months before study enrollment.\n4. Presence of concurrent bacterial or fungal infection.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "99 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "Patients who are 18 years of age or older, who have a persistent corneal epitheliopathy due to neurotrophic keratopathy that is refractory to conventional non-surgical treatments for 2 weeks or more, and who fulfill the inclusion and exclusion criteria detailed above.",
            "samplingMethod": "PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Simon Fung, MD",
                    "role": "CONTACT",
                    "phone": "310-794-9581",
                    "email": "simonfung@mednet.ucla.edu"
                }
            ],
            "locations": [
                {
                    "facility": "University of California, Los Angeles",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90095",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Simon Fung, MD",
                            "role": "CONTACT",
                            "phone": "310-206-7202",
                            "email": "simonfung@mednet.ucla.edu"
                        },
                        {
                            "name": "Simon Fung, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Anthony Aldave, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Saba Al-Hashimi, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Sophie Deng, MD, PhD",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "24672223",
                    "type": "BACKGROUND",
                    "citation": "Sacchetti M, Lambiase A. Diagnosis and management of neurotrophic keratitis. Clin Ophthalmol. 2014 Mar 19;8:571-9. doi: 10.2147/OPTH.S45921. eCollection 2014."
                },
                {
                    "pmid": "10889110",
                    "type": "BACKGROUND",
                    "citation": "Bonini S, Lambiase A, Rama P, Caprioglio G, Aloe L. Topical treatment with nerve growth factor for neurotrophic keratitis. Ophthalmology. 2000 Jul;107(7):1347-51; discussion 1351-2. doi: 10.1016/s0161-6420(00)00163-9."
                },
                {
                    "pmid": "22543481",
                    "type": "BACKGROUND",
                    "citation": "Lambiase A, Sacchetti M, Bonini S. Nerve growth factor therapy for corneal disease. Curr Opin Ophthalmol. 2012 Jul;23(4):296-302. doi: 10.1097/ICU.0b013e3283543b61."
                },
                {
                    "pmid": "29653861",
                    "type": "BACKGROUND",
                    "citation": "Bonini S, Lambiase A, Rama P, Filatori I, Allegretti M, Chao W, Mantelli F; REPARO Study Group. Phase I Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis. Ophthalmology. 2018 Sep;125(9):1468-1471. doi: 10.1016/j.ophtha.2018.03.004. Epub 2018 Apr 10. No abstract available."
                },
                {
                    "pmid": "30683186",
                    "type": "BACKGROUND",
                    "citation": "Ting DSJ. Re: Bonini et al.: Phase 2 randomized, double-masked, vehicle-controlled trial of recombinant human nerve growth factor for neurotrophic keratitis (Ophthalmology. 2018;125:1332-1343). Ophthalmology. 2019 Feb;126(2):e14-e15. doi: 10.1016/j.ophtha.2018.09.017. No abstract available."
                },
                {
                    "pmid": "31585826",
                    "type": "BACKGROUND",
                    "citation": "Pflugfelder SC, Massaro-Giordano M, Perez VL, Hamrah P, Deng SX, Espandar L, Foster CS, Affeldt J, Seedor JA, Afshari NA, Chao W, Allegretti M, Mantelli F, Dana R. Topical Recombinant Human Nerve Growth Factor (Cenegermin) for Neurotrophic Keratopathy: A Multicenter Randomized Vehicle-Controlled Pivotal Trial. Ophthalmology. 2020 Jan;127(1):14-26. doi: 10.1016/j.ophtha.2019.08.020. Epub 2019 Aug 26."
                },
                {
                    "pmid": "32387431",
                    "type": "BACKGROUND",
                    "citation": "Mastropasqua L, Lanzini M, Dua HS, D' Uffizi A, Di Nicola M, Calienno R, Bondi J, Said DG, Nubile M. In Vivo Evaluation of Corneal Nerves and Epithelial Healing After Treatment With Recombinant Nerve Growth Factor for Neurotrophic Keratopathy. Am J Ophthalmol. 2020 Sep;217:278-286. doi: 10.1016/j.ajo.2020.04.036. Epub 2020 May 6."
                }
            ],
            "seeAlsoLinks": [
                {
                    "label": "Related Info",
                    "url": "https://link.springer.com/article/10.1007/s40135-020-00228-y"
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000007634",
                    "term": "Keratitis"
                }
            ],
            "ancestors": [
                {
                    "id": "D000003316",
                    "term": "Corneal Diseases"
                },
                {
                    "id": "D000005128",
                    "term": "Eye Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10660",
                    "name": "Keratitis",
                    "asFound": "Keratitis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6539",
                    "name": "Corneal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8271",
                    "name": "Eye Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC11",
                    "name": "Eye Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009883",
                    "term": "Ophthalmic Solutions"
                }
            ],
            "ancestors": [
                {
                    "id": "D000019999",
                    "term": "Pharmaceutical Solutions"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M21860",
                    "name": "Pharmaceutical Solutions",
                    "relevance": "LOW"
                },
                {
                    "id": "M12814",
                    "name": "Ophthalmic Solutions",
                    "asFound": "Anxiety",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "PhSol",
                    "name": "Pharmaceutical Solutions"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}